Viberzi

Chemical Nameeluxadoline
Dosage FormTablet (oral; 75 mg, 100 mg)
Drug ClassReceptor antagonists
SystemDigestive
CompanyAllergan
Approval Year2015

Indication

  • To treat irritable bowel syndrome with diarrhea (IBS-D) in adult men and women.
Last updated on 3/10/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Viberzi (eluxadoline) Prescribing Information2018Allergan USA, Inc., Madison, NJ
Document TitleYearSource
Canadian Association of Gastroenterology Clinical Practice guideline for the management of irritable bowel syndrome (IBS). 2020Journal of the Canadian Association of Gastroenterology